Glaukos (GKOS)
(Delayed Data from NYSE)
$119.82 USD
+2.17 (1.84%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $119.74 -0.08 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$119.82 USD
+2.17 (1.84%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $119.74 -0.08 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Zacks News
Glaukos (GKOS) Up on Positive Glaucoma Study Data on iDose TR
by Zacks Equity Research
Glaukos' (GKOS) targeted injectable implant candidate, iDose TR, achieves a non-inferior reduction in IOP in patients with open-angle glaucoma versus daily treatment with timolol.
Why Is Glaukos (GKOS) Down 8.7% Since Last Earnings Report?
by Zacks Equity Research
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Glaukos (GKOS) Strong Portfolio Driving Sales Amid Competition
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and a strong pipeline. However, stiff competition remains a woe.
Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of -88.64% and 7.51%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights McKesson, AmerisourceBergen, LHC Group and Glaukos
by Zacks Equity Research
McKesson, AmerisourceBergen, LHC Group and Glaukos are part of Zacks top Analyst Blog.
Medical Device Stocks' Earnings on Aug 3: MCK, ABC & More
by Indrajit Bandyopadhyay
Medical Device players are likely to have benefited from the reopening of economies and several efforts to combat staffing challenges. Let's see how MCK, ABC, LHCG and GKOS fare this time.
Teleflex (TFX) Q2 Earnings Beat Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 1.19% and 2.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Integra (IART) Q2 Earnings Top, 2022 Adjusted EPS View Cut
by Zacks Equity Research
Integr's (IART) year-over-year growth in both the CSS and Tissue Technology segments buoys optimism.
Align Technology (ALGN) Q2 Earnings Lag Estimates, Margins Drop
by Zacks Equity Research
The dull underlying market situation, impacted by macro-economic environmental factors and lingering effects of COVID-19 variants in certain markets, impacts Align Technology's (ALGN) Q2 results.
Boston Scientific (BSX) Q2 Earnings Beat, Margins Decline
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Henry Schein's (HSIC) Q2 performance will likely reflect continued strength in its dental and medical businesses.
IDEXX (IDXX) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
IDEXX's (IDXX) Q2 performance will likely benefit from strong sales from the CAG Diagnostics and Water businesses.
Edwards Lifesciences (EW) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Edwards Lifesciences' (EW) Q2 performance will likely reflect the continued adoption of the RESILIA tissue valves and enhanced sales of the HemoSphere platform.
Exact Sciences (EXAS) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Exact Sciences' (EXAS) Q2 performance will likely reflect the benefit from continued adoption of the Oncotype DX breast test and robust Cologuard screening revenues.
Charles River (CRL) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Key Surgical and Cantel Medical businesses make significant contributions to consumable revenues within the Healthcare arm in Q1.
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Supply constraints, along with inflationary pressures, is likely to have weighed on DaVita's (DVA) second quarter's top line.
Intuitive Surgical (ISRG) Q2 Earnings Miss, Procedures Recover
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect health demand for procedures despite the resurgence of COVID-19 infections.
Here's Why Glaukos (GKOS) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Glaukos (GKOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is a Beat Likely for Intuitive Surgical (ISRG) in Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Best Momentum Stocks to Buy for July 13th
by Zacks Equity Research
JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.
Here's Why You Should Add Glaukos (GKOS) to Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Has Glaukos (GKOS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Glaukos (GKOS) and Alkermes (ALKS) have performed compared to their sector so far this year.